Skip to content
value.today

Corvex, Inc.

MOVE
$283 Mmarket cap on Oct 30, 2026+501.3% since Jan 2024
1M
-31.8%
Compare
World rank
#15,018
Revenue
$0 M
For year ending December-2025
Net income
$-18 M
-4251.2% margin
SEC filing
Employees
—

Corvex, Inc. in brief

Corvex, Inc. is a listed company in the Healthcare sector, based in California, USA. It was founded in 2018. Its market value was $283 M on 30 October 2026, which makes it the 15,018th largest listed company in the world and the 2,927th largest in the USA on this site. In the year to December 2025 it had sales of $0 M and a net loss of $18 M. Its largest business segments by sales in 2025 were Segment Reporting (100%). Its shares trade under the symbol MOVE (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Corvex, Inc.

On March 19, 2026, we consummated and completed the Merger pursuant to the Merger Agreement, as further described below. Following the closing of the Merger, the Company will conduct its operations through two primary business divisions. Our AI cloud computing business specializes in GPU-accelerated infrastructure for AI workloads and our healthcare business consists of our wellness ring (formerly referred to as the Evie Ring), a wearable designed specifically for women that was launched in November 2023.

On March 19, 2026, Corvex, Inc. (formerly known as Movano Inc.), acquired Corvex Legacy Holdings, Inc. (formerly known as Corvex, Inc.), in accordance with the terms of the Amended and Restated Agreement and Plan of Merger, dated March 19, 2026, by and among Corvex, Thor Merger Sub Inc., a Delaware corporation and a wholly-owned subsidiary of the Company, and Corvex OpCo. Pursuant to the Merger Agreement, Merger Sub merged with and into Corvex OpCo, pursuant to which Corvex OpCo was the surviving corporation and became a wholly owned subsidiary of the Company. The Merger Agreement amended and restated in its entirety the prior merger agreement between the parties which was entered into and announced on November 6, 2025.

Corvex, Inc. timeline

5 events, 2018–2026
  1. 2018
  2. 🏁
    · approximate
    Founded
  3. ✎
    Renamed Movano Inc.
    Formerly Maestro Sensors Inc..
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2021
  6. 🔔
    · approximate
    Initial public offering on Nasdaq
  7. 2026
  8. ✎
    Renamed Corvex, Inc.
    Formerly Movano Inc..

Events of Corvex, Inc. from the company record and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$112 M$224 M$336 M$448 M2023202420252026

World rank over time

▲ up 6,444 places since 2022
2022-01-07: #21504#21,50420222022-12-25: #25304#25,30420222023-07-30: #23457#23,45720232024-01-05: #25222#25,22220242026-03-08: #12395#12,39520262026-08-01: #13925#13,92520262026-10-07: #13476#13,47620262026-10-30: #15060#15,0602026

Rank in USA: #4,210 (Jan 2022) · #4,794 (Dec 2022) · #4,500 (Jul 2023) · #4,092 (Jan 2024) · #2,337 (Mar 2026) · #2,811 (Aug 2026) · #2,642 (Oct 2026) · #2,931 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
657.2×
Price / book
—
Free cash flow yield
-8.0%
Net margin
-4251.2%
Operating margin
-3604.7%
Return on equity
—
Liabilities / assets
162.0%
Revenue growth
-57.4%
R&D / revenue
1334.9%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2020: revenue —, net income $-13M—FY20Fiscal year ending Dec 2021: revenue —, net income $-22M—FY21Fiscal year ending Dec 2022: revenue —, net income $-30M—FY22Fiscal year ending Dec 2023: revenue —, net income $-29M—FY23Fiscal year ending Dec 2024: revenue $1M, net income $-24M$1MFY24Fiscal year ending Dec 2025: revenue $0M, net income $-18M$0MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$0M-57.4%$-16M$-18M-4251.2%
Dec 2024$1M—$-24M$-24M-2349.5%
Dec 2023——$-30M$-29M—
Dec 2022——$-30M$-30M—
Dec 2021——$-20M$-22M—
Dec 2020——$-11M$-13M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-11M——$-21.79—
Dec 2024$-23M$0M$-23M$-39.39—
Dec 2023$-26M$0M$-26M$-9.51—
Dec 2022$-25M$0M$-25M$-0.92$2.97
Dec 2021$-16M$1M$-17M$-0.92—
Dec 2020$-11M——$-6.85—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $0M, net income $-5M$0MDec ’24Three months to Mar 2025: revenue $0M, net income $-5M$0MMar ’25Three months to Jun 2025: revenue $0M, net income $-3M$0MJun ’25Three months to Sep 2025: revenue $0M, net income $-4M$0MSep ’25Three months to Dec 2025 (from the annual report): revenue $0M, net income $-6M$0MDec ’25Three months to Mar 2026: revenue $1M, net income $-5M$1MMar ’26Three months to Jun 2026: revenue $4M, net income $-13M$4MJun ’26Three months to Sep 2026: revenue $5M, net income $-18M$5MSep ’26

Latest quarter to Sep 2026: revenue $5M (+6125.0% on a year earlier), net income $-18M. Lighter bars: fourth quarters worked out from the annual report.

SEC filings

Official filings of Corvex, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$0 M
Operating income
$-16 M
Net income
$-18 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$6 M
Total liabilities
$9 M
Total equity
$-3 M

As of December-2025

Top 30 institutional investors in Corvex, Inc.#

As of Sep 30, 2026
30 institutions held 2.1 M shares (about 5.3% of the shares outstanding) on Sep 30, 2026. The ten largest hold 4.7%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Corvex, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Accurate Wealth Management, LLC498,646New1.27%$6 MOct 20, 2026
2Weiss Asset Management LP258,000New0.66%$3 MNov 16, 2026
3BlackRock, Inc.233,969+227,988 (+3811.87%)0.60%$3 MNov 13, 2026
4Morgan Stanley199,484+193,903 (+3474.34%)0.51%$2 MNov 13, 2026
5Vanguard Capital Management LLC184,558+162,982 (+755.39%)0.47%$2 MNov 13, 2026
6Geode Capital Management, LLC172,873+153,886 (+810.48%)0.44%$2 MNov 6, 2026
7State Street Corp94,629New0.24%$1 MNov 12, 2026
8Vanguard Fiduciary Trust Co88,640+80,248 (+956.24%)0.23%$1 MNov 13, 2026
9Northern Trust Corp58,978+32,717 (+124.58%)0.15%$1 MNov 16, 2026
10Raymond James Financial Inc58,723+12,746 (+27.72%)0.15%$1 MNov 12, 2026
11Millennium Management LLC35,813New0.09%$0 MNov 16, 2026
12Dorsey & Whitney Trust CO LLC33,182-17,787 (-34.90%)0.08%$0 MNov 13, 2026
13Peak6 LLC31,435New0.08%$0 MNov 13, 2026
14Oppenheimer & Co Inc28,689New0.07%$0 MOct 26, 2026
15Susquehanna International Group, LLP22,072New0.06%$0 MNov 16, 2026
16UBS Group AG17,116+16,291 (+1974.67%)0.04%$0 MNov 10, 2026
17Colonial Trust Advisors10,469New0.03%$0 MNov 10, 2026
18Aster Capital Management (DIFC) Ltd8,355New0.02%$0 MNov 12, 2026
19Vanguard Global Advisers, LLC6,333New0.02%$0 MNov 13, 2026
20Tower Research Capital LLC (TRC)4,057+2,889 (+247.35%)0.01%$0 MNov 16, 2026
21Barclays PLC3,651+3,468 (+1895.08%)0.01%$0 MNov 6, 2026
22Clearstead Advisors, LLC3,1400 (0.00%)0.01%$0 MNov 6, 2026
23Pinnacle Financial Group, Inc.1,600—0.00%$0 MNov 16, 2026
24Northwestern Mutual Wealth Management Co1,0040 (0.00%)0.00%$0 MNov 13, 2026
25Citigroup Inc306New0.00%$0 MNov 4, 2026
Show all 30: investors 26 to 30
Institutional investors 26 to 30 in Corvex, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Osaic Holdings, Inc.200+133 (+198.51%)0.00%$0 MNov 12, 2026
27Jpmorgan Chase & Co142+53 (+59.55%)0.00%$0 MNov 12, 2026
28Royal Bank Of Canada98+29 (+42.03%)0.00%$0 MNov 16, 2026
29Evolution Wealth Management Inc.40 (0.00%)0.00%$0 MOct 28, 2026
30Simplex Trading, LLC1New0.00%$0 MNov 4, 2026

Mutual funds holding Corvex, Inc.#

7 funds hold shares worth $1 M (about 0.1% of the company). Since their previous reports 7 added shares and 0 sold, buying $1 M net.
Mutual funds holding Corvex, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.21,576$0 M0.06%<0.01%+251%Jun 30, 2026
🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc.6,491$0 M0.02%0.04%newJun 30, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors5,250$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC4,937$0 M0.01%<0.01%+6.1%May 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC1,558$0 M<0.01%<0.01%+36%May 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC1,438$0 M<0.01%<0.01%+36%May 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC346$0 M<0.01%<0.01%newJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 7 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Corvex, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$1.5 M
20 sales, 3 insiders
Net, 12 months
-$1.5 M
open market only
Insiders on file
14
since
$261 K-$1.5 M$0Nov 2023: bought $261 K (3 trades), sold $0 (0 trades)Nov 23Apr 2024: bought $0 (5 trades), sold $0 (0 trades)AprJan 2026: bought $0 (0 trades), sold $1.5 M (20 trades)Jan 26
Bought (open market)Sold (open market)Hover a month for the totals
Corvex, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Seth DemseyCo-Chief Executive Officer, DirectorConversion+5.48 M——8.56 MForm 4
filed John Adler Crystal IIICo-Chief Executive Officer, DirectorConversion+3.35 M——6.41 MForm 4
filed Emily FairbairnDirectorConversionindirect+1.21 M——1.21 MForm 4
filed Seth DemseyCo-Chief Executive Officer, DirectorConversionindirect+31,270——31,409Form 4
filed John Adler Crystal IIICo-Chief Executive Officer, DirectorConversionindirect+708,154——711,321Form 4
filed Patrick FleuryDirectorGrant or award+100,000——100,000Form 4
filed Christopher MorelandCFOGrant or award+523,211——523,211Form 4
filed Emily FairbairnDirectorGrant or award+135,800——228,577Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Corvex, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
586,889
47.8% of shares · 6.86 days to cover

Trading halts

  • 2026-11-12 14:30 UTC, code LUDP, resumed 14:35 UTC

Fails to deliver

  • : 971 shares at $7.22
  • : 4,828 shares at $7.57
  • : 1,509 shares at $8.07
  • : 2,245 shares at $8.45
  • : 100 shares at $8.54

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Corvex, Inc. scorecard#

Passes 0 of the 14 checks that could be worked out. Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation0 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
    • ✗Price to sales below its peers' median657.2×Price to sales 657.2× against Healthcare's median of 3.8×.
    • ✗Free cash flow yield above 5%-8.0%Free cash flow is -8.0% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-21.79 vs -39.39Diluted EPS -21.79 in fiscal 2025 against -39.39 the year before (report's currency).
    • ✗Net income higher than five years earlier-$18 M-$18 M in fiscal 2025 against -$13 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 2
    • ✗Profitable in the newest year-$18 MNet income -$18 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health0 of 4
    • ✗Short-term assets cover short-term liabilities0.6×Current ratio 0.57 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • ✗Operating income covers interest five times-5.2×Operating income -5.2 times interest in fiscal 2025.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-32.78Z-score -32.78 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year39.7%Diluted shares up 39.7% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Healthcare, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Corvex, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Corvex, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020
Income statement
Revenue0.41.0————
Cost of revenue2.33.0————
Research and development5.7111719138.4
General and administrative7.91113116.42.7
Operating expenses——30302011
Total costs and expenses162530———
Operating income−16−24−30−30−20−11
Interest expense and finance costs3.0——0.80.91.0
Net interest income———0.1−2.0−1.9
Other non-operating income (expense)−2.80.50.40.1——
Income before tax−18—————
Net income including minority interests————−22−13
Net income attributable to shareholders−18−24−29−30−22−13
Earnings per share, basic-21.79-39.39r-9.51r-0.92-0.92-6.85
Earnings per share, diluted-21.79-39.39r-9.51r-0.92r-0.92-6.85
Shares, weighted average (basic)0.80.6r3.1r3326—
Shares, weighted average (diluted)0.80.6r3.1r33r263.2
Dividends per share———2.97——
Balance sheet
Cash and cash equivalents2.87.96.111185.7
Short-term investments————16r—
Inventory1.82.01.1———
Other current assets0.4r0.40.40.4r1.30.7
Current assets5.0108.512356.9
Property, plant and equipment0.10.20.30.40.50.0
Right-of-use (leased) assets0.40.6r0.0r0.4——
Total assets5.6119.413367.1
Accounts payable3.52.03.10.60.30.2
Current liabilities8.83.45.95.03.21.2
Lease liabilities (non-current)0.30.5r0.0r———
Non-current liabilities0.30.50.10.40.314
Total liabilities9.14.06.05.33.515
Retained earnings−166−148−124−95−65−41
Shareholders' equity−3.57.43.47.933−41
Total equity————33—
Total liabilities and equity5.6119.413367.1
Shares outstanding1.2r0.7r3.7r34r336.4
Cash-flow statement
Depreciation and amortization0.10.20.20.10.10.0
Share-based compensation2.93.23.03.11.90.4
Cash from operating activities−11−23−26−25−16−11
Capital expenditure—−0.0−0.1−0.1−0.6—
Cash from investing activities—−0.0−0.116−17—
Debt issued1.5————12
Shares issued1.61.73.22.20.10.7
Cash from financing activities6.224222.34512
Change in cash———−6.912—
Report10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Corvex, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue. Lines can overlap (a total and its parts), so they are not added up.

Business segments

  • Segment Reporting$0 M100%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Where Corvex, Inc. operates: 2 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 3 subsidiaries on file.

Corvex, Inc.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters1 office2 subsidiaries—
🇮🇪 Ireland1 subsidiary—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Events at Corvex, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Auditor changedFiling
  • Delisting noticeFiling
  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 3 · Auditor changed 1 · Change in control 1 · Directors and officers 4 · Material agreement 5 · New debt 1 · Unregistered share sale 4 · Shareholder rights changed 2 · Bylaws or fiscal year changed 4 · Shareholder vote 3 · Results announced 6

Corvex, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Material agreement8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Directors and officersUnregistered share saleBylaws or fiscal year changedShareholder vote8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Auditor changed8-K
Delisting noticeDirectors and officersMaterial agreementUnregistered share saleShareholder rights changedBylaws or fiscal year changed8-K
Results announced8-K
Directors and officersShareholder vote8-K
Change in controlMaterial agreementNew debtUnregistered share saleBylaws or fiscal year changed8-K
Material agreement8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Delisting notice8-K
Shareholder vote8-K
Delisting notice8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

1 acquisitions · 2 private funding rounds before listing

Businesses it acquired

Acquisitions by Corvex, Inc.
AcquiredAcquisition dateCompletionPriceStakeSource
Merger AgreementNov 2025———Annual report

Private share sales · funding history

Private share sales of Corvex, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2026$33 MPrivate placement after listing$10 to $50 million26equitySEC
Apr 2024$24 MPrivate placement after listing$10 to $50 million185equity, optionsSEC
Mar 2019$10 MNo. 2$10 to $50 million183equity, optionsSEC
Mar 2018$6 MNo. 1$2 to $10 million22equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at Corvex, Inc.#

2 labor condition applications certified in fiscal 2025 for 2 positions, at a median wage of $160 K a year.

Certified, FY2025
2
#1,608 among companies on value.today
Worker positions
2
Median wage offered
$160 K
a year, full-time
Applications filed
2
Corvex, Inc.: most frequent H-1B job titles in fiscal 2025
Job titlePositionsMedian wage offered
Manager, Quality SystemsQuality Control Systems Managers1$136 K
Sr. Embedded Firmware EngineerSoftware Developers1$185 K

Where: Pleasanton, CA 2

Corvex, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202522$160 K2
FY202311$185 K1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Movano Inc

How Corvex, Inc. compares in Healthcare

  • Market cap$283 M · higher than 38% of 2,013
  • Revenue$0 M · higher than 9% of 1,795
  • Revenue growth-57.4% · higher than 8% of 1,003
  • Price / sales657.2× · lower than 0% of 1,071
  • FCF yield-8.0% · higher than 45% of 835
CompanyMarket capP/ENet marginRev. growth
Corvex, Inc.🇺🇸$283 M——-57.4%
Eli Lilly and Company🇺🇸$1.20 T43.4×31.9%+44.7%
Johnson & Johnson🇺🇸$652.5 B40.5×16.2%+6.0%
AbbVie Inc.🇺🇸$514.0 B49.7×15.7%+8.6%
Roche Holding AG🇨🇭$370.3 B29.1×19.0%—
UnitedHealth Group Incorporated🇺🇸$367.7 B23.1×3.5%+11.8%
Merck & Co., Inc.🇺🇸$359.8 B146.7×3.6%+1.3%
Novartis AG🇨🇭$286.8 B20.5×24.7%—
Thermo Fisher Scientific Inc.🇺🇸$253.8 B35.9×14.9%+3.9%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Corvex, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Corvex, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Corvex, Inc.? Suggest a correction